serine palmitoyltransferase long chain base subunit 2Genealiases: HSN1C · LCB2 · LCB2A · NSAN1C · SPT2 · hLCB2a
Q-omics provides the consensus-scored SPTLC2 profile across patient tissues and cancer cell-line models. SPTLC2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPTLC2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SPTLC2 RNA expression shows 20,034 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where SPTLC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTLC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTLC2 survival associations across molecular data types. SPTLC2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTLC2 RNA expression–survival associations across cancer types. High SPTLC2 expression shows unfavorable associations in ACC, MESO, LIHC and LGG, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPTLC2 RNA expression.
This table summarizes SPTLC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SPTLC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTLC2 shows lower tumor expression in KIRC and higher tumor expression in LIHC, BLCA, BRCA, CHOL and STAD. The KIRC box plot shows higher SPTLC2 RNA expression in normal versus tumor tissue (log2 FC = −0.572, t-test p < 0.001).
This table shows molecular features associated with SPTLC2 in patient tissues and cancer cell lines. In patient samples, SPTLC2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTLC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
